Clin2
NCT05507879Possibly a fitRecruiting

Breast cancer heart monitoring to predict heart damage risk

Breast CarcinomaCardiomyopathyCongestive Heart Failure

Part of Cancer, Heart & circulation, Skin clinical trials.

This trial studies how a blood test marker (TRPC6) may help predict and prevent heart muscle damage and heart failure related to some breast cancer medicines. You may join if you’re starting or have received treatment that can stress the heart, or if you already have signs of treatment-related heart problems.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
200 people
Ages
18 years and older
Study type
Observational

Who can take part

  • Be 18 years or older
  • Have breast cancer and be starting (or recently finished) medicines that can affect the heart, like doxorubicin/other anthracyclines or trastuzumab
  • Have a history of heart-related side effects from cancer treatment, or be starting potentially heart-harming medicines
  • Be able to understand the study and sign consent
  • Agree to blood draws (the study requires getting blood samples)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT01173341Enrolling by invitation
Checking heart side effects of breast cancer treatments

This study looks at how breast cancer medicines affect the heart. It may help doctors better prevent, spot early, and manage heart side effects from trastuzumab and/or anthracycline chemotherapy.

Philadelphia, Pennsylvania
NCT07588425Not yet recruiting
Monitoring heart health during breast cancer treatment

This study watches how chemotherapy and HER2-targeted drugs affect your heart during early-stage breast cancer treatment. Researchers use heart scans to catch any changes early and understand how to protect heart health.

Ankara, Ankara
NCT03418961Recruiting· Phase 3
Study of heart-risk management for metastatic HER2 breast cancer

This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.

Anchorage, Alaska
NCT07663357Recruiting
Blood test to detect heart damage from breast cancer treatment

This study looks at whether a simple blood test can spot early signs of heart damage from certain breast cancer treatments (anthracycline chemo or anti-HER2 drugs). The goal is to protect your heart while you get the cancer treatment you need.

Fortaleza, Ceará
NCT07528586Recruiting
Heart Imaging Study During Cancer Drug Treatment

This study uses heart imaging scans and blood tests to check if a common cancer drug (anthracycline) is affecting your heart during treatment. Early detection might help doctors protect your heart health.

Stuttgart
NCT02772367Recruiting
Make heart muscle cells from blood or skin in breast cancer

This study grows heart muscle cells from your blood or skin to better understand why some people develop heart problems from HER2 cancer treatments. You may be helping researchers learn how to predict and prevent treatment-related heart damage.

New York, New York

Hear when a new Breast Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.